Compare Dishman Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA STRIDES PHARMA SCIENCE DISHMAN PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 25.1 42.1 59.6% View Chart
P/BV x 3.3 2.0 170.4% View Chart
Dividend Yield % 0.7 0.2 268.4%  

Financials

 DISHMAN PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
STRIDES PHARMA SCIENCE
Mar-18
DISHMAN PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3741,147 32.6%   
Low Rs129642 20.1%   
Sales per share (Unadj.) Rs197.8317.2 62.3%  
Earnings per share (Unadj.) Rs21.27.8 270.3%  
Cash flow per share (Unadj.) Rs34.725.1 138.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.2 355.5%  
Book value per share (Unadj.) Rs179.9274.3 65.6%  
Shares outstanding (eoy) m80.6989.50 90.2%   
Bonus / Rights / Conversions -ESOP-  
Price / Sales ratio x1.32.8 45.1%   
Avg P/E ratio x11.9114.0 10.4%  
P/CF ratio (eoy) x7.235.7 20.3%  
Price / Book Value ratio x1.43.3 42.9%  
Dividend payout %9.425.5 37.0%   
Avg Mkt Cap Rs m20,30680,058 25.4%   
No. of employees `0000.82.5 33.1%   
Total wages/salary Rs m5,3554,341 123.4%   
Avg. sales/employee Rs Th19,252.711,325.8 170.0%   
Avg. wages/employee Rs Th6,459.51,731.4 373.1%   
Avg. net profit/employee Rs Th2,064.1280.1 737.0%   
INCOME DATA
Net Sales Rs m15,96128,394 56.2%  
Other income Rs m265941 28.2%   
Total revenues Rs m16,22629,334 55.3%   
Gross profit Rs m4,1033,965 103.5%  
Depreciation Rs m1,0911,540 70.8%   
Interest Rs m9441,962 48.1%   
Profit before tax Rs m2,3341,403 166.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-168 -0.7%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m62497 640.9%   
Profit after tax Rs m1,711702 243.7%  
Gross profit margin %25.714.0 184.1%  
Effective tax rate %26.76.9 385.4%   
Net profit margin %10.72.5 433.6%  
BALANCE SHEET DATA
Current assets Rs m11,01824,836 44.4%   
Current liabilities Rs m9,51718,993 50.1%   
Net working cap to sales %9.420.6 45.7%  
Current ratio x1.21.3 88.5%  
Inventory Days Days11071 155.7%  
Debtors Days Days35113 30.7%  
Net fixed assets Rs m16,30434,289 47.5%   
Share capital Rs m161895 18.0%   
"Free" reserves Rs m12,90723,651 54.6%   
Net worth Rs m14,51624,546 59.1%   
Long term debt Rs m4,18915,513 27.0%   
Total assets Rs m29,80565,437 45.5%  
Interest coverage x3.51.7 202.4%   
Debt to equity ratio x0.30.6 45.7%  
Sales to assets ratio x0.50.4 123.4%   
Return on assets %8.94.1 218.8%  
Return on equity %11.82.9 412.1%  
Return on capital %17.56.9 254.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95215,697 31.5%   
Fx outflow Rs m697735 94.8%   
Net fx Rs m4,25514,962 28.4%   
CASH FLOW
From Operations Rs m2,7861,871 148.9%  
From Investments Rs m-1,5295,826 -26.2%  
From Financial Activity Rs m-941-10,157 9.3%  
Net Cashflow Rs m316-2,615 -12.1%  

Share Holding

Indian Promoters % 61.4 27.7 221.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 37.8 9.8%  
FIIs % 12.7 8.6 147.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 25.9 85.3%  
Shareholders   46,261 56,241 82.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA  SANOFI INDIA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Up 50 Points; Indicates Positive Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a positive note today. At 8:05 am, it was trading up by 50 points, or 0.3% higher at 14,760 levels.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS